Knowledge HQ

The authors engineered CARs with a PDZ binding motif to improve immune synapse formation, leading to enhanced anti-tumor activity in NK and T cells. During the generation of CD19-CAR T cells, the transduced cells were expanded in G-Rex 10 and then G-Rex 100.

This review compares CIK cells to CAR-T cells, highlighting CIK advantages. It notes that G-Rex devices enable efficient, GMP-compliant expansion of CIK cells with simplified protocols, facilitating decentralized manufacturing and reducing costs compared to traditional bioreactors.

The study identifies neoantigen-reactive TCRs from TILs by sorting for CD39, PD-1, and TIGIT co-expression. While these cells are dysfunctional, their TCRs can be used for engineering. Sorted TIL populations were plated in G-Rex 24-well plates for rapid expansion (REP) to assess functional reactivity.

The authors developed a protocol for generating allogeneic CD33-CAR-T cells using CRISPR-Cas9 to knockout HLA-I/TCR and Sleeping Beauty transposon for CAR delivery. This approach generated functional CAR-T cells. Electroporated CAR-T cells were expanded at large scale using the G-Rex platform.

This study demonstrates a GMP-compliant protocol for expanding donor-derived γδ T cells using zoledronic acid, IL-2, and engineered aAPCs. The method achieved significant expansion of Vδ1 and Vδ2 subsets. PBMCs were seeded into G-Rex 100 for the initial enrichment and expansion phases.

Describes a non-viral CRISPR/Cas9 HITI method for CAR knock-in. Primary T cells were cultivated in G-Rex 24-well/6-well plates or G-Rex 100M vessels.

Developed a GMP process for gene correction of CD4+ T cells. Medium-scale experiments used G-Rex 6-6M, and large-scale used G-Rex 100CS or 500CS for cell expansion.

This study presents preclinical data for allogeneic CD20xCD22 CAR T cells. Cells were cultured in 10 cm G-Rex or 6-well G-Rex devices during the manufacturing process.

The study creates synthetic promoters for CAR-T cells. T cells nucleofected with piggyBac transposase were transferred to G-REX culture vessels for 21 days of expansion.

Describes a thaw/wash method for CAR-T cells for intracranial delivery. B7-H3-CAR T cells were generated and expanded in G-Rex culture devices using X-VIVO 15 media with cytokines.

This study generates BCMA-CAR Vg9Vd2 T cells via mRNA electroporation. Vg9Vd2 T cells were expanded using Zometa and co-cultured with aAPCs. Previous work by the group used G-Rex vessels for large-scale expansion.

This clinical study evaluates humanized CD19 CAR-T cells in pediatric R/R ALL with CNS issues. Transduced T cells were cultured, amplified, and harvested over 5–7 days using the G-Rex system.